Herbal blend for male ageing symptoms loses to placebo

Male climacteric syndrome describes the cluster of psychological, somatic, sexual and endocrine-related symptoms some men report with ageing, and it can meaningfully affect quality of life. That combination — real symptoms, fluctuating hormones, and no simple treatment — has made it fertile ground for botanical supplements marketed for vitality and testosterone. Testing such products properly requires a placebo comparator, because symptom scores in this area are notoriously variable and responsive to expectation. This trial asked whether a specific plant extract combination outperformed placebo on a validated symptom scale.

The investigators ran a 12-week, randomised, double-blind, placebo-controlled trial in 70 men aged 45 to 75 years with male climacteric syndrome, registered in advance. Participants received either the botanical formulation of Elaeagnus multiflora fruit and Cynanchum wilfordii extracts at 1500 mg/day or a matching placebo. The primary outcome was the change in Aging Males' Symptoms total score from baseline to week 12. Secondary outcomes included the symptom subdomains, Androgen Deficiency in Aging Males positivity, hormonal parameters, lipid profile and safety. Efficacy was analysed in the per-protocol population of 64 men, and safety in all 70.

The formulation did not demonstrate superiority over placebo on the primary outcome. Symptom scores improved markedly in both arms — by -14.2 ± 12.5 points with treatment and -15.5 ± 12.3 with placebo — with no significant between-group difference (p = 0.6726). Subdomain scores and Androgen Deficiency in Aging Males positivity also improved in both groups without any significant separation. Free testosterone rose non-significantly in the treatment group (+0.8 ± 2.4 pg/mL, p = 0.0727) and significantly in the placebo group (+1.3 ± 2.6 pg/mL, p = 0.0076), yet the between-group comparison was null (p = 0.8720). No treatment-related serious adverse events occurred.

This is a clean negative result in a field where uncontrolled studies routinely report improvement, and it illustrates exactly why: the placebo arm improved as much as the active arm, and even a hormonal measure moved significantly in the placebo group. The authors attribute the pattern to placebo responsiveness, regression to the mean and symptom variability. It leaves open whether other doses, longer exposure or different populations could yield an effect, and the authors argue future trials need standardised repeated morning testosterone measurements, since single readings are unreliable.

The useful lesson is broader than one product. Symptoms attributed to male ageing improve substantially even on placebo over a few months, so before-and-after testimonials — including apparent hormone changes — are weak evidence of anything. For this particular extract combination at this dose and duration, there was no measurable advantage over a dummy capsule, and no short-term safety signal either way. Longer-term safety remains unknown from a 12-week study. Men troubled by these symptoms have a genuine clinical issue worth raising with a doctor rather than a supplement question.